Dale A. Stringfellow
Keine laufenden Positionen mehr
Profil
Dr. Stringfellow was President and CEO of Berlex Laboratories, from December 2000 until April, 2003.
Berlex is a wholly-owned subsidiary of Schering AG and is responsible for all of Schering's pharmaceutical operations in the U.S.
From 1995 to 2000, Dr. Stringfellow was President of Berlex Biosciences which is responsible for all of Schering's research and development in the U.S.
In August 2002, Dr. Stringfellow became Chairman of Collateral Therapeutics, a wholly-owned subsidiary of Schering AG.
He has been a director of Myriad Genetics Inc. since December 1991.
From July 1990 until April 1995, he was President, CEO and a director of Celtrix Pharmaceuticals.
Dr. Stringfellow has also held other positions including: Vice President and Senior Director of Preclinical Cancer Research at Bristol-Myers Company;
Ehemalige bekannte Positionen von Dale A. Stringfellow
| Unternehmen | Position | Ende |
|---|---|---|
Collateral Therapeutics, Inc.
 Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Vorsitzender | 11.10.2007 |
Berlex, Inc.
 Berlex, Inc. Pharmaceuticals: MajorHealth Technology Berlex, Inc. manufactured pharmaceutical company. It developed novel diagnostics and therapeutics, which address unmet medical needs. It used to researches, develops, manufactures and markets ethical pharmaceuticals in five strategic areas such as female healthcare, diagnostic imaging, dermatology, oncology and therapeutics. The company was headquartered in Wayne, NJ | Präsident | 01.04.2003 |
| MYRIAD GENETICS, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Dale A. Stringfellow
| University of Utah | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Berlex, Inc.
Berlex, Inc. Pharmaceuticals: MajorHealth Technology Berlex, Inc. manufactured pharmaceutical company. It developed novel diagnostics and therapeutics, which address unmet medical needs. It used to researches, develops, manufactures and markets ethical pharmaceuticals in five strategic areas such as female healthcare, diagnostic imaging, dermatology, oncology and therapeutics. The company was headquartered in Wayne, NJ | Health Technology |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Commercial Services |
